Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Active not recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Peritoneal Neoplasms 1Ovarian Neoplasms 1Metastatic Adenocarcinoma of the Pancreas 1Fallopian Tube Neoplasms 1Carcinoma 1

Interventions

Trastuzumab 9Capecitabine 7trastuzumab deruxtecan 6Paclitaxel 6Fulvestrant 6pertuzumab 5eribulin 5Gemcitabine 4Cyclophosphamide 4sacituzumab govitecan 3Vinorelbine 3Doxorubicin 3Docetaxel 3Ado-Trastuzumab Emtansine 3130-nm albumin-bound paclitaxel 3selpercatinib 2ribociclib 2palbociclib 2olaparib 2larotrectinib 2exemestane 2abemaciclib 2Fluorouracil 2Epirubicin 2Carboplatin 2ulixertinib 1tucatinib 1trastuzumab biosimilar HLX02 1trametinib 1taxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Breast Neoplasms × 130-nm albumin-bound paclitaxel × Clear all
NCT05374512 2026-05-15

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

AstraZeneca

Phase 3 Active not recruiting
644 enrolled 1 FDA
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04494425 2026-03-04

DB-06

AstraZeneca

Phase 3 Active not recruiting
866 enrolled 25 charts 1 FDA
Breast

Breast Neoplasms

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Daiichi Sankyo

Phase 3 Active not recruiting
557 enrolled 22 charts 1 FDA
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡